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Allogeneic hematopoietic cell transplantation (HCT), but not autologous HCT, can provide long-term remis-
sion in some patients with adult T cell leukemia-lymphoma (ATL). We retrospectively analyzed the effects of
acute graft-versus-host disease (GVHD) among the 616 patients with ATL who survived at least 30 days after
allogeneic HCT with other than cord blood grafts. Multivariate analyses treating the occurrence of GVHD as
a time-varying covariate demonstrated an association between grade I-II acute GVHD and favorable overall
survival (OS) (hazard ratio [HR], 0.634; 95% conﬁdence interval [CI], 0.477 to 0.843), whereas grade III-IV
acute GVHD showed a trend toward unfavorable OS (HR, 1.380; 95% CI, 0.988 to 1.927) compared with
nonacute GVHD. In subsequent multivariate analyses of patients who survived at least 100 days after HCT
(n ¼ 431), the presence of limited chronic GVHD showed a trend toward favorable OS (HR, 0.597; 95% CI,
0.354 to 1.007), and extensive chronic GVHD had a signiﬁcant effect on OS (HR, 0.585; 95% CI, 0.389 to 0.880).
There were no signiﬁcant interactions between myeloablative conditioning or reduced-intensity conditioning
with OS even when acute GVHD was absent or present at grade I-II or grade III-IV or when chronic GVHD was
absent, limited, or extensive. This study demonstrates the actual existence of graft-versus-ATL effects in
patients with ATL regardless of whether myeloablative conditioning or reduced-intensity conditioning is
used.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Adult T cell leukemia-lymphoma (ATL) is an aggressive
peripheral T cell neoplasm caused by human T cell lympho-
tropic/leukemia virus type 1 (HTLV-1). It has a very poor
prognosis, and it has been generally accepted that conven-
tional chemotherapeutic agents alone, even including zido-
vudine/IFN-a, yield few or no long-term remissions or
potential cures in patients with ATL [1-6]. Although early
experience in myeloablative chemoradiotherapy together
with autologous hematopoietic cell rescue for ATL has beendgments on page 1738.
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13.09.014associated with high incidences of relapse and fatal toxicities
[7], allogeneic hematopoietic cell transplantation (HCT) has
been explored as a promising alternative treatment that can
provide long-term remission in a proportion of patients with
ATL [8-10].
We previously performed a nationwide retrospective
study of patients with ATL who underwent allogeneic HCT in
Japan, with special emphasis on the effect of the graft source.
We concluded that allogeneic HCT using currently available
sources is an effective treatment in selected patients with
ATL, but that the use of unrelated cord blood as a stem cell
source is associated with lower survival [11]. Our results
suggest that allogeneic bone marrow transplantation (BMT)
and peripheral blood stem cell transplantation (PBSCT) could
be considered the more standard transplantation forms
compared with unrelated cord blood transplantation (CBT)
for ATL.Transplantation.
Table 1
Patient and Transplantation Characteristics by Type of Conditioning
Regimen
Characteristic MAC RIC P Value
Total patients, n (%) 284 (46.1) 332 (53.9)
Age at HCT, y, n (%)
<50 178 (62.7) 43 (13.0) <.0001
51-55 79 (27.8) 91 (27.4)
56-60 20 (7.0) 125 (37.7)
61þ 7 (2.5) 73 (22.0)
Sex, n (%)
Male 159 (56.0) 160 (48.2) .0628
Female 125 (44.0) 172 (51.8)
Disease status at HCT, n (%)
CR 104 (36.6) 128 (38.6) .1013
Not in CR 161 (56.7) 194 (58.4)
Unknown 19 (6.7) 10 (3.0)
GVHD prophylaxis, n (%)
CyA þ MTX 129 (45.4) 112 (33.7) <.0001
FK506 þ MTX 142 (50.0) 147 (44.3)
CyA 6 (2.1) 58 (17.5)
FK506 5 (1.8) 13 (3.9)
Unknown 2 (0.7) 2 (0.6)
Stem cell source, n (%)
BM 216 (76.1) 213 (64.2) .0015
PBSCs 68 (23.9) 117 (35.2)
BM þ PBSCs 0 (0.0) 2 (0.6)
Donorerecipient relationship, n (%)
HLA-matched related 98 (34.5) 120 (36.1) .3649
HLA-mismatched related 24 (8.5) 40 (12.0)
Unrelated 160 (56.3) 171 (51.5)
Unknown 2 (0.7) 1 (0.3)
PS at HCT, n (%)
0 111 (39.1) 144 (43.4) .0012
1 127 (44.7) 154 (46.4)
2 26 (9.2) 27 (8.1)
3 3 (1.1) 5 (1.5)
4 1 (0.4) 1 (0.3)
Unknown 16 (5.6) 1 (0.3)
ATL clinical subtype, n (%)
Chronic/smoldering 11 (3.9) 10 (3.0) .5278
Acute 171 (60.2) 189 (56.9)
Lymphoma 80 (28.2) 97 (29.2)
Unknown 22 (7.7) 36 (10.8)
Time from diagnosis to HCT, d, n (%)
16-153 82 (28.9) 72 (21.7) .0632
154-204 64 (22.5) 88 (26.5)
205-307 75 (26.4) 78 (23.5)
308-4355 63 (22.2) 91 (27.4)
Unknown 0 (0.0) 3 (0.9)
Time of HCT, n (%)
March 1995 to March 2005 75 (26.4) 79 (23.8) .3119
April 2005 to May 2007 75 (26.4) 79 (23.8)
June 2007 to February 2009 73 (25.7) 81 (24.4)
March 2009 to December 2010 61 (21.5) 93 (28.0)
Grade of acute GVHD, n (%)
No acute GVHD 80 (28.2) 128 (38.6) .0111
Grade I-II 148 (52.1) 159 (47.9)
Grade III-IV 56 (19.7) 45 (13.6)
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tive study of patients with ATL who underwent allogeneic
HCT other than CBT, with special emphasis on the effects of
the preconditioning regimen, whether conventional mye-
loablative conditioning (MAC) or reduced-intensity condi-
tioning (RIC). No signiﬁcant difference in overall survival (OS)
was observed between patients receiving MAC and those
receiving RIC, but a trend toward RIC contributing to better
OS in older patients was noted. Thus, we conclude that
allogeneic HCT not only with MAC, but also with RIC, is an
effective treatment resulting in long-term survival in
selected patients with ATL [12].
ATL has a long latency and occurs in older individuals
at a median age of nearly 66 years. The median age at diag-
nosis of ATL has been increasing over the last few decades
[13]. Accordingly, the proportion of patients with ATL
undergoingHCTwith RIC is currently increasing in relation to
HCT with MAC. It is thought that compared with HCT with
MAC, allogeneic HCT with RIC depends more on donor
cellular immune effects after transplantation and less on the
cytotoxic effects of the conditioning regimen to eradicate
residual tumor cells. In this context, RIC might be suitable
for ATL, given that several reports have indicated the high
immunogenicity of ATL cells [14-18] and even the existence of
graft-versus-HTLV-1 and/or graft-versus-ATL effects [19-21].
Although we previously reported the impact of
post-transplantation immune reactions, graft-versus-host
disease (GVHD), on outcomes in patients with ATL [21], our
cohort included CBT recipients whose OS curve had a quite
different trajectory from that of BMT and PBSCT recipients
[12]. Thus, in the present study, we evaluated whether acute
and chronic GVHD affect outcomes in patients with ATL
undergoing allogeneic HCT other than unrelated CBT, with
special emphasis on the effects of the preconditioning
regimen. Our present analysis included the previous cohort
(1996 to 2005) [21] with updated clinical information, as
well as data on 1 patient who underwent allogeneic HCT in
1995 and patients who underwent allogeneic HCT between
2006 and 2010.
PATIENTS AND METHODS
Data Collection
Data on patients with ATL who had undergone a ﬁrst allogeneic BMT,
PBSCT, or BMT þ PBSCT were collected from nationwide survey data of the
Japan Society for Hematopoietic Cell Transplantation (JSHCT). Cases with
missing preconditioning information, acute GVHD, or survival data were
excluded, leaving 679 patients. Because the association between the
occurrence of acute GVHD and disease-associated mortality was difﬁcult to
evaluate in the event of early toxic death, patients who died within 30 days
or were censored within 29 days of transplantation (n ¼ 63) were excluded;
thus, 616 patients who underwent HCT between March 1995 and December
2010 were included in our analysis.
Data collected for analysis included clinical characteristics, such as age at
HCT, sex, disease status at HCT, date of HCT, time from diagnosis of ATL to
HCT, performance status (PS) according to the Eastern Cooperative Oncology
Group criteria at transplantation, stem cell source, donorerecipient rela-
tionship, ATL clinical subtype [22], preconditioning regimen, type of GVHD
prophylaxis, date alive at last follow-up, date and cause of death, date of
occurrence of acute GVHD and maximum grade of acute GVHD, and grade
and date of occurrence of chronic GVHD. The studywas approved by the Data
Management Committees of the JSHCT, as well as by the Institutional Ethics
Committee of Nagoya City University Graduate School of Medical Sciences.
Deﬁnitions
OS was deﬁned as the time from HCT until death, and patients who
remained alive at the time of the last follow-up were censored. Reported
causes of deathwere reviewed and categorized into ATL-relatedmortality or
treatment-related mortality (TRM). ATL-related mortality was deﬁned as
death caused by relapse or progression of ATL based on the judgment of each
institution. TRM was deﬁned as any death other than ATL-related mortality.Acute GVHD was diagnosed and graded using traditional criteria [23] by the
physicians who performed HCT at each institution, as was chronic GVHD
[24]. Among the 487 patients who survived at least 100 days after HCT, 431
patients with complete information on the grade and the day of occurrence
of chronic GVHD were included in the analysis for chronic GVHD.
Patients undergoing allogeneic BMT or PBSCT were divided into 2
groups, MAC and RIC, based on the preconditioning regimen. MAC and RIC
were deﬁned according to Giralt et al. [25] and Bacigalupo et al. [26] with
slight modiﬁcations. In the present study, MAC was deﬁned as any regimen
that includes (1) 5 Gy of total body irradiation (TBI) as a single fraction or
8 Gy fractionated, (2) busulfan >8 mg/kg orally or the i.v. equivalent, or (3)
melphalan >140 mg/m2. All other regimens were classiﬁed as RIC.
Statistical Analysis
Comparisons among the groups were performed using Fisher’s exact
test as appropriate for categorical variables. The probability of survival was
Figure 1. Semi-landmark plots illustrating the effects of acute GVHD on
survival, ATL-related mortality, and TRM. (A) HR for survival in patients with
grade I-II and grade III-IV acute GVHD compared with patients with no acute
GVHD: 0.681 (95% CI, 0.537 to 0.863) versus 1.437 (95% CI, 1.082 to 1.910). (B)
HR for ATL-related mortality in patients with grade I-II and grade III-IV acute
GVHD compared with patients with no acute GVHD: 0.729 (95% CI, 0.540 to
0.984) versus 0.624 (95% CI, 0.403 to 0.967). (C) HR for TRM in patients with
grade I-II and grade III-IV acute GVHD compared with patients with no acute
GVHD: 0.824 (95% CI, 0.552 to 1.232) versus 2.793 (95% CI, 1.884 to 4.229).
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were estimated using cumulative incidence curves to accommodate the
competing events ATL-related mortality for TRM and TRM for ATL-related
mortality [27]. Semilandmark plots were used to illustrate the effects of
GVHD on survival and the cumulative incidence of ATL-relatedmortality and
TRM. This landmarkmethodwas used to exclude bias that might have arisen
from including patients who died too early to develop GVHD in the group
without GVHD [28,29]. For patients with acute or chronic GVHD, the prob-
ability of survival and the cumulative incidences of ATL-related mortality
and TRMwere plotted as functions of time from the onset of acute or chronic
GVHD. Day 25, the median day of onset for acute GVHD (range, 6 to 166
days), was designated the landmark day for acute GVHD. Day 126, the
median day of onset for chronic GVHD (range, 52 to 1203 days), was
designated the landmark day for chronic GVHD.
Multivariate Cox proportional hazards regression models were used to
evaluate variables potentially affecting OS, and Fine and Gray proportional
subdistribution hazards models [30] were used to evaluate variables
potentially affecting ATL-related mortality and TRM. In these regression
models, the occurrence of acute and chronic GVHD was treated as a time-
varying covariate [31]. In the analysis of acute GVHD, patients were
assigned to the no acute GVHD group at the time of HCTand then transferred
to the grade I-II acute GVHD group or to the grade III-IV acute GVHD group at
the onset of acute GVHD. In the analysis of chronic GVHD, patients were
assigned to the no chronic GVHD group at the time of HCT and then trans-
ferred to the limited chronic GVHD group or to the extensive chronic GVHD
group at the onset of chronic GVHD. We also assessed the interaction
between acute and chronic GVHD and the preconditioning regimen in the
multivariate models.
The heterogeneities of the effects of grade I-II or III-IV acute GVHD on OS
according to background transplantation characteristics were evaluated by
forest plots stratiﬁed by variables included in the regression analyses.
Results are expressed as hazard ratio (HR) with 95% conﬁdence interval (CI).
All tests were 2-sided, and a P value <.05 was considered to indicate
statistical signiﬁcance. All statistical analyses were performed by Kureha
Special Laboratory (Tokyo, Japan) using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Among the 616 patients in the study cohort, 284 received
MAC and the remaining 332 received RIC. Characteristics of
these patients are summarized in Table 1. Compared with
MAC recipients, signiﬁcantly fewer RIC recipients belonged
to the youngest age group (<50 years), and signiﬁcantly
more were in the 2 oldest age groups (56 to 60 and 61þ
years). In addition, signiﬁcantly fewer RIC recipients received
cyclosporin A (CyA) þ methotrexate (MTX), but signiﬁcantly
more received CyA without MTX. PBSCT was signiﬁcantly
more frequent in RIC recipients compared with MAC recipi-
ents. There was no signiﬁcant difference between MAC and
RIC recipients regarding PS distribution from 0 to 4, but an
unknown PS was observed signiﬁcantly more frequently in
the MAC recipients. A signiﬁcantly greater number of RIC
recipients did not have acute GVHD, and signiﬁcantly fewer
had grade III-IV acute GVHD.
Effects of Acute GVHD on Survival
In the 208 patients with ATL and no acute GVHD, the
unadjusted 1-year and 3-year probabilities of survival from
the landmark day for acute GVHDwere 45.4% (95% CI, 38.3 to
52.2%) and 37.3% (95% CI, 30.3 to 44.4%), respectively. The
unadjusted 1-year and 3-year probabilities of survival from
the onset of acute GVHDwere 60.1% (54.2 to 65.5%) and 49.1%
(43.0 to 55.0%), respectively, in the 307 patients with grade I-
II acute GVHD and 36.4% (26.9 to 46.0%) and 21.7% (13.9 to
30.6%), respectively, in the 101 patients with grade III-IV
acute GVHD (Figure 1A).
Forest plots revealed that the development of grade I-II
acute GVHD was associated with longer OS compared with
the absence of acute GVHD in patients with the following
characteristics: age <56 years, either male or female, not in
complete remission (CR), receiving FK506 þ MTX,undergoing either BMT or PBSCT, having an unrelated donor,
PS 1 at transplantation, acute type of ATL, interval between
ATL diagnosis and HCT of 308 to 4355 days, and date of HCT
between June 2007 and February 2009. The development of
grade I-II acute GVHD was also signiﬁcantly associated with
longer OS compared with the absence of acute GVHD
regardless of whether the patient received MAC or RIC. On
the other hand, this comparison revealed a shorter OS in the
patients with lymphoma type ATL (Figure 2). These plots also
revealed that the development of grade III-IV acute GVHD
Figure 2. Impact of the grade of acute GVHD on OS in each stratiﬁed category. Effects of grade I-II (A) and grade III-IV acute GVHD (B) on OS are shown as forest plots.
Closed ellipses on lines indicates HRs compared with the no acute GVHD group, and horizontal lines represent the corresponding 95% CI.
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the absence of acute GVHD in patients with PS 0 and who
underwent HCT between March 2009 and December 2010.
However, this comparison revealed no signiﬁcant ﬁndings
for OS according to whether the patient received MAC or RIC
(Figure 2).
Multivariate analysis of the 616 study patients was per-
formed to examine whether acute GVHD affects OS using the
following variables: age (15 to 55 or 56 to 72 years), sex,
disease status at HCT (CR, not CR, or unknown), pre-
conditioning regimen (MAC or RIC), GVHD prophylaxis
(CyA þMTX, FK506 þMTX, or other/unknown), relationship
between recipient and donor (HLA-matched related, HLA-
mismatched related, or unrelated), PS (0, 1, 2 to 4, or
unknown), ATL clinical subtype (chronic/smoldering, acute,
lymphoma, or unknown), time from diagnosis to HCT (16 to
153,154 to 204, 205 to 307, or 308 to 4355 days or unknown),
date of HCT (March 1995 to March 2005, April 2005 to May
2007, June 2007 to February 2009, or March 2009 to
December 2010), and source of stem cells (bone marrow
[BM], peripheral blood stem cells [PBSCs], or BMþ PBSCs), as
well as acute GVHD as a time-dependent covariate (no, grade
I-II, or grade III-IV). There was a signiﬁcant positive impact of
grade I-II acute GVHD on OS (HR, 0.634; 95% CI, 0.477 to
0.843) compared with no acute GVHD (Table 2).
To further investigate the clinical signiﬁcance of acute
GVHD for OS, we divided acute GVHD into 5 categories (none
or grade I, II, III, or IV) and then performed multivariateanalysis in the same manner as described above. HRs for OS
of patients with grade I, II, III, and IV acute GVHD compared
with the absence of acute GVHD were 0.568 (95% CI, 0.402 to
0.801), 0.688 (95% CI, 0.501 to 0.946), 1.199 (95% CI, 0.831 to
1.730), and 2.245 (95% CI, 1.354 to 3.722), respectively.
Interactions of the Preconditioning Regimen with Acute
GVHD for OS
We tested statistical interactions between the pre-
conditioning regimens and acute GVHD with regard to OS by
adding an interaction term to the multivariate analysis. This
analysis included the same variables as the multivariate Cox
proportional hazards regression models for OS. Among the
616 patients, when the HR for death of MAC recipients with
no acute GVHD was set as 1.000, the HRs in MAC recipients
with grade I-II acute GVHD and in RIC recipients with no
GVHD and with grade I-II acute GVHD were 0.659, 0.971, and
0.592, respectively (Pinteraction ¼ .7962), and the HRs in MAC
and RIC recipients with grade III-IV acute GVHD were 1.343
and 1.387, respectively (Pinteraction ¼ .7603) (Figure 3A).
Effects of Acute GVHD on ATL-Related Mortality and TRM
Among the 616 patients receiving allogeneic BMT or
PBSCT, 10 patients could not be assigned to either the ATL-
related mortality or TRM category because of missing
detailed information on the cause of death. The cumulative
incidences of ATL-related mortality at 1 year and 3 years
from the landmark day for acute GVHD were 35.0% (95% CI,
Table 2
Effect of Acute GVHD on OS, ATL-related Mortality, and TRM after Allogeneic
HCT
Outcome HR (95% CI) P Value
OS*
No acute GVHD 1.000 Reference
Grade I-II acute GVHD 0.634 (0.477-0.843) .0017
Grade III-IV acute GVHD 1.380 (0.988-1.927) .0590
ATL-related mortalityy
No acute GVHD 1.000 Reference
Grade I-II acute GVHD 0.833 (0.566-1.224) .3511
Grade III-IV acute GVHD 0.599 (0.373-0.964) .0347
TRMz
No acute GVHD 1.000 Reference
Grade I-II acute GVHD 0.645 (0.407-1.023) .0624
Grade III-IV acute GVHD 2.474 (1.495-4.095) .0004
* Other than acute GVHD, the following 4 variables signiﬁcantly affected
OS: older age (56 to 72 yr compared with 15 to 55 yr: HR, 1.356; 95% CI,
1.033 to 1.781), male sex (HR, 1.404; 95% CI, 1.127 to 1.750), not in CR
compared with CR (HR, 1.877; 95% CI, 1.459 to 2.416), and worse PS (1
compared with 0: HR, 1.486; 85% CI, 1.168 to 1.889; 2 to 4 compared with 0:
HR, 2.691; 95% CI, 1.918 to 3.777).
y Other than acute GVHD the following 2 variables signiﬁcantly affected
ATL-related mortality: not in CR compared with CR (HR, 2.633; 95% CI, 1.818
to 3.814) and worse PS (2 to 4 compared with 0: HR, 3.272; 95% CI, 2.100 to
5.099).
z Other than acute GVHD, the following 3 variables signiﬁcantly affected
TRM: older age (56 to 72 yr compared with 15 to 55 yr: HR, 1.663; 95% CI,
1.025 to 2.697), male sex (HR, 1.545; 95% CI, 1.078 to 2.214), and trans-
plantation from an unrelated donor compared with an HLA-matched related
donor (HR, 2.098; 95% CI, 1.131 to 3.895).
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tively, in the 203 patients with no acute GVHD. Those of TRM
were 20.0% (95% CI, 13.5% to 27.5%) and 22.0% (95% CI, 14.8%
to 30.1%), respectively (Figure 1B and C). The cumulative
incidences of ATL-related mortality at 1 year and 3 years
from the onset of acute GVHD were 25.8% (95% CI, 20.5% to
31.4%) and 33.0% (95% CI, 26.9% to 39.3%), respectively, in the
304 patients with grade I-II acute GVHD, whereas those of
TRM were 14.5% (95% CI, 10.1% to 19.6%) and 18.5% (95% CI,
13.0% to 24.6%), respectively (Figure 1B and C). In the 99
patients with grade III-IV acute GVHD, the cumulative inci-
dences of ATL-related mortality at 1 year and 3 years from
the onset of acute GVHD were 21.2% (95% CI, 10.8% to 33.8%)
and 27.0% (95% CI, 14.2% to 41.5%), respectively, and those of
TRM were 42.7% (95% CI, 31.8% to 53.3%) and 50.7% (95% CI,
38.6% to 61.7%), respectively (Figure 1B and C).
We next applied the Fine and Gray proportional hazards
model to the 606 patients. The analysis included the sameFigure 3. Interactions of the preconditioning regimen with acute GVHD for overall su
RIC) and acute GVHD (absent versus grade I-II or grade II-IV; A) and chronic GVHD (variables as in the multivariate Cox proportional hazards
regressionmodels for OS. There were signiﬁcant associations
between grade III-IV acute GVHD and lower ATL-related
mortality (HR, 0.599; 95% CI, 0.373 to 0.964) and higher
TRM (HR, 2.474; 95% CI, 1.495 to 0.964) compared with no
acute GVHD (Table 2).
In investigating the clinical signiﬁcance of acute GVHD for
ATL-related mortality or TRM, we divided acute GVHD into 5
categories (none and grade I, II, III, and IV) and conducted the
analysis in the samemanner as described above. HRs for ATL-
related mortality in patients with grade I, II, III, and IV acute
GVHD compared with the absence of acute GVHDwere 0.809
(95% CI, 0.517 to 1.268), 0.857 (95% CI, 0.558 to 1.315), 0.585
(95% CI, 0.347 to 986), and 0.654 (95% CI, 0.298 to 1.435),
respectively. HRs for TRM in patients with grade I, II, III, and
IV acute GVHD compared with the absence of acute GVHD
were 0.519 (95% CI, 0.282 to 0.955), 0.747 (95% CI, 0.455 to
1.227), 2.153 (95% CI, 1.267 to 3.659), and 4.114 (95% CI, 2.033
to 8.326), respectively.Effects of Chronic GVHD on Survival
Among the 431 patients evaluable for chronic GVHD, 199
received MAC and 232 received RIC. In the MAC group,
limited and extensive chronic GVHD occurred in 26 (13.1%)
and 67 patients (33.7%), respectively, and in the RIC group,
limited and extensive chronic GVHD occurred in 35 (15.1%)
and 65 patients (28.0%), respectively. Regarding the inci-
dence and grade of chronic GVHD, there were no signiﬁcant
differences between MAC and RIC recipients. In the 214
patients with no chronic GVHD, the unadjusted 1-year and 3-
year probabilities of survival from the landmark day for
chronic GVHD were 58.7% (95% CI, 51.6 to 65.1%) and 51.0%
(95% CI, 43.6 to 57.9%), respectively,. Those probabilities from
the onset of chronic GVHD were 77.4% (64.2 to 86.2%) and
61.7% (46.7 to 73.6%), respectively, in the 60 patients with
limited chronic GVHD and were 70.4% (61.7 to 77.5%) and
55.1% (45.5 to 63.7%), respectively, in the 132 patients with
extensive chronic GVHD. Twenty-ﬁve patients were
excluded from this semilandmark plot because they were
censored or died before the landmark day for chronic GVHD
(Figure 4A).
We performed a multivariate analysis of data on 431
patients to examine whether chronic GVHD affects OS using
the following variables: age, sex, disease status, pre-
conditioning regimen, GVHD prophylaxis, donorerecipient
relationship, PS, ATL clinical subtype, time from diagnosis torvival. Statistical interactions between the preconditioning regimens (MAC or
absent versus limited or extensive type; B) for overall survival were analyzed.
Figure 4. Semilandmark plots illustrating the effects of chronic GVHD on
survival, ATL-related mortality, and TRM. (A) HR for survival in patients with
limited and extensive chronic GVHD compared with patients with no chronic
GVHD: 0.719 (95% CI, 0.457 to 1.131) versus 0.796 (95% CI, 0.576 to 1.100). (B)
HR for ATL-related mortality in patients with limited and extensive chronic
GVHD compared with patients with no chronic GVHD: 0.461 (95% CI, 0.237 to
0.897) versus 0.570 (95% CI, 0.366 to 0.886). (C) HR for TRM in patients with
limited and extensive chronic GVHD compared with patients with no chronic
GVHD: 1.609 (95% CI, 0.815 to 3.175) versus 1.620 (95% CI, 0.955 to 2.749).
Table 3
Effect of Chronic GVHD on OS, ATL-related Mortality, and TRM after Allo-
geneic HCT
Outcome HR (95% CI) P Value
OS*
No chronic GVHD 1.000 Reference
Limited chronic GVHD 0.597 (0.354-1.007) .0533
Extensive chronic GVHD 0.585 (0.389-0.880) .0100
ATL-related mortalityy
No chronic GVHD 1.000 Reference
Limited chronic GVHD 0.395 (0.184-0.847) .0170
Extensive chronic GVHD 0.421 (0.240-0.740) .0026
TRMz
No chronic GVHD 1.000 Reference
Limited chronic GVHD 1.549 (0.704-3.409) .2767
Extensive chronic GVHD 1.204 (0.659-2.201) .5462
* Other than chronic GVHD, the following 3 variables signiﬁcantly
affected OS: male sex (HR, 1.480; 95% CI, 1.103 to 1.986), not in CR compared
with CR (HR, 1.629; 95% CI, 1.171 to 2.266), worse PS (1 compared with 0:
HR, 1.446; 95% CI, 1.057 to 1.980, 2 to 4 compared with 0: HR, 2.828; 95% CI,
1.751 to 4.568).
y Other than chronic GVHD, the following 2 variables signiﬁcantly
affected ATL-related mortality: not in CR compared with CR (HR, 2.499; 95%
CI, 1.563 to 3.994), worse performance score (1 compared with 0: HR, 1.524;
95% CI, 1.013 to 2.294, 2 to 4 compared with 0: HR, 2.383; 95% CI, 1.216 to
4.669).
z The following 4 variables signiﬁcantly affected TRM: older age (56 to 72
yr compared with 15 to 55 yr: HR, 2.022; 95% CI, 1.045 to 3.913), male sex
(HR, 2.254; 95% CI1.322 to 3.844), worse performance score (2 to 4
compared with 0: HR, 3.127; 95% CI, 1.260 to 7.762), and ATL clinical
subtype (acute compared with chronic/smoldering type: HR, 0.288; 95% CI,
0.093 to 0.897; lymphoma compared with chronic/smoldering type: HR,
0.249; 95% CI, 0.078 to 0.794).
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GVHD as a time-dependent covariate. We found a signiﬁcant
positive impact of extensive chronic GVHD on OS compared
with no chronic GVHD (HR, 0.585; 95% CI, 0.389 to 0.880)
(Table 3).
Interactions of the Preconditioning Regimen with
Chronic GVHD for OS
We tested the statistical interactions between the pre-
conditioning regimens and chronic GVHD for OS by addingan interaction term into the multivariate analysis. The anal-
ysis included the same variables as the multivariate Cox
proportional hazards regression models for OS with chronic
GVHD. Among the 431 patients, when the HR for death of
MAC recipients with no chronic GVHD was set as 1.000, the
HRs in MAC recipients with limited chronic GVHD and RIC
recipients with no GVHD and limited chronic GVHD were
0.845, 1.159, and 0.536, respectively (Pinteraction ¼ .1502), and
the HRs in MAC and RIC recipients with extensive chronic
GVHDwere 0.565 and 0.689, respectively (Pinteraction¼ .9413)
(Figure 3B).
Effects of Chronic GVHD on ATL-Related Mortality and
TRM
Among the 406 patients analyzed by a semilandmark plot
for survival, 9 could not be assigned to either the ATL-related
mortality or TRM category. The cumulative incidences of
ATL-related mortality at 1 year and 3 years from the land-
mark day for chronic GVHD were 29.0% (95% CI, 22.4% to
35.8%) and 33.7% (95% CI, 26.4% to 41.1%), respectively, in the
208 patients with no chronic GVHD, whereas those of TRM
were 12.0% (95% CI, 7.3% to 18.1%) and 13.9% (95% CI, 8.5% to
20.7%), respectively (Figure 4B and C). In the 59 patients with
limited chronic GVHD, the cumulative incidences of ATL-
related mortality at 1 year and 3 years from the onset of
chronic GVHD were 7.0% (95% CI, 2.1% to 16.1%) and 18.3%
(95% CI, 7.7% to 32.4%), respectively, and those of TRM were
16.0% (95% CI, 7.5% to 27.4%) and 20.8% (95% CI, 10.1% to
34.1%), respectively (Figure 4B and C). In the 130 patients
with extensive chronic GVHD, the cumulative incidences of
ATL-related mortalities at 1 year and 3 years from the onset
of chronic GVHDwere 15.1% (95% CI, 9.0% to 22.6%) and 23.1%
(95% CI, 14.7% to 32.6%), respectively, and those of TRM were
15.0% (95% CI, 9.1% to 22.3%) and 21.6% (95% CI, 13.9% to
30.5%), respectively (Figure 4B and C).
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model to the 422 patients evaluable for chronic GVHD who
could be assigned to either the ATL-related mortality or the
TRM category. The analysis included the same variables as
the multivariate Cox proportional hazards regression models
for OS. Chronic GVHD was signiﬁcantly associated with
reduced ATL-related mortality. HRs for recipients with
limited and extensive chronic GVHD compared with the
absence of chronic GVHD were 0.395 (95% CI, 0.184 to 0.847)
and 0.421 (95% CI, 0.240 to 0.740), respectively (Table 3). On
the other hand, chronic GVHD was not signiﬁcantly associ-
ated with TRM.
DISCUSSION
To the best of our knowledge, this is the largest retro-
spective study reported to date analyzing the impact of acute
and chronic GVHD on clinical outcomes in ATL. As shown in
Table 1, the associations with no acute GVHD and without
grade III-IV acute GVHD were signiﬁcant in RIC recipients
comparedwithMAC recipients. Those ﬁndings are consistent
with reports of an association between dose-intensiﬁed
conditioning, especially regimens including TBI, and acute
GVHD [32,33]. Our results also show no signiﬁcant difference
in the occurrence of chronic GVHD between MAC and RIC
recipients. This may be because the effects of older age and
more frequent PBSCT, which increase the occurrence of
chronic GVHD, were counterbalanced by the lower frequency
of history of previous acute GVHD, which reduces the inci-
dence of chronic GVHD, in the RIC recipients [32,34].
Forest plots revealed that the development of grade I-II
acute GVHD was associated with favorable OS compared
with the absence of acute GVHD in most categories, with the
exception of lymphoma in the ATL clinical subtype category.
The reason for this exception is unclear, however. Our forest
plots also show that the occurrence of grade III-IV acute
GVHD was associated with unfavorable OS in most
categories.
The signiﬁcant positive impact of grade I-II acute GVHD
on OS identiﬁed by multivariate analysis conﬁrmed the
results presented in our previous report [21]. However, in the
present study, we found that grade I-II acute GVHD had no
signiﬁcant association with ATL-related mortality, in
disagreement with our previous report showing a signiﬁcant
association between grade I-II acute GVHD and decreased
ATL-related mortality in ATL patients undergoing allogeneic
HCT [21]. We surmise that the incompatibility might stem
from 2 factors, the inﬂuence of unrelated CBT, which was
included in the previous study [21], and the progress in
transplantation-related medicine from 2006 onward. The
clear trend of decreased TRM in patients with grade I-II acute
GVHD observed here seems a bit puzzling, but we have no
suitable explanation. With respect to preconditioning, there
were no signiﬁcant interactions betweenMAC and RIC for OS
even when post-transplantation acute GVHD was absent or
present at grade I-II or III-IV.
Our multivariate analysis revealed a clear trend toward
a favorable OS with limited chronic GVHD and a signiﬁcant
association with lower ATL-related mortality. These ﬁndings
are consistent with previous reports by our group [20] and
others [35]. The latter report included a variety of hemato-
logic diseases. Even though our univariate analyses revealed
a trend toward better survival (but without signiﬁcance) in
patients with extensive chronic GVHD in the semilandmark
plots (Figure 4A), our multivariate analysis demonstrated
that a signiﬁcant association between extensive chronicGVHD and a favorable OS. This ﬁnding is in disagreement
with our previous report [21] and another study demon-
strating a negative impact of extensive chronic GVHD on OS
[35]. Extensive chronic GVHD had a signiﬁcant association
with lower ATL-related mortality, but not with TRM. The
former ﬁnding was reasonable and expected, but the latter
was not consistent with our previous report demonstrating
signiﬁcant associations between extensive chronic GVHD
and greater TRM [21]. Although the present study found
a signiﬁcant association between extensive chronic GVHD
and favorable OS in the patients with ATL, we also must pay
special attention to the fact that quality of life after HCT is
highly compromised by chronic GVHD [36]. With respect to
preconditioning, there were also no signiﬁcant interactions
betweenMAC and RIC with OS evenwhen chronic GVHDwas
absent, limited, or extensive.
Several promising new agents for treating ATL are
currently under development [37-40]. These novel treat-
ments should increase the number of patients with a sufﬁ-
cient disease control status and who have maintained a good
PS who could become suitable candidates for HCT [12]. These
agents will also contribute to the establishment of better
rescue strategies for patients relapsing after HCT [41]. Among
the novel agents, we should pay special attention to moga-
mulizumab (humanized anti-CCR4 monoclonal antibody)
[42], whichwas approved for the treatment of ATL in Japan in
2012, because of its potent activity that depletes regulatory T
(Treg) cells, leading to enhanced antitumor activity
[38,43,44]. The occurrence and severity of GVHD are closely
associated with low Treg frequency [45]; thus, a decrease in
Treg cells caused by mogamulizumab not only may lead to
enhanced GVHD, but also may provoke an anti-HTLV-1/ATL
immune effect.
Although this study reports signiﬁcant novel ﬁndings on
GVHD in patients with ATL, it also has inherent limitations
common to observational retrospective studies. First, eligi-
bility for HCT as well as choice of transplantation protocol,
including the selection of MAC or RIC, were determined by
physicians at each institution. Second, regarding analysis of
mortality, it was not always easy to determinewhether death
after allogeneic HCT was an ATL-related mortality or TRM, in
part because patients with relapsed ATL sometimes achieve
partial or complete remission after decreasing or dis-
continuing immunosuppressive agents, donor lymphocyte
infusions, or chemotherapy, which can result in long-term
remission and survival [20]. Third, acute GVHD is occasion-
ally induced in some patients considered at high risk for
relapse by treating clinicians. Finally, the evaluation of
chronic GVHD according to the 2005 National Institutes of
Health consensus criteria [46] is not possible in this study,
which was based on nationwide survey data of the JSHCT.
In conclusion, we found that the development of mild to
moderate (grade I-II) acute GVHD was signiﬁcantly associ-
ated with favorable OS, as was the development of both
limited and extensive chronic GVHD. Regarding pre-
conditioning, we found no difference in the clinical impact of
acute GVHD and chronic GVHD on OS between patients
receiving MAC and those receiving RIC. These ﬁndings
conﬁrm the actual existence of graft-versus-HTLV-1 and/or
graft-versus-ATL effects in recipients of HCT for ATL regard-
less of whether MAC or RIC was used. New strategies that
enhance the post- transplantation allogeneic antieHTLV-1
effect targeting HTLV-1eassociated antigens, such as Tax
and/or HBZ [14-17], and/or the anti-ATL effect targeting
tumor-speciﬁc antigens, such as cancer testis antigens [18],
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patients undergoing allogeneic HCT for ATL.ACKNOWLEDGMENTS
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